AcquisitionsJul 20, 2026, 09:26 AM
Personalis to be Acquired by Tempus AI for $1.5B
AI Summary
Personalis, Inc. announced it has entered into a definitive agreement to be acquired by Tempus AI, Inc. for $16.25 per share, valuing the company at $1.5 billion. This represents a 6% premium to Personalis' closing price and a 28% premium to its unaffected 30-day VWAP. The acquisition, expected to close in late 2026 or early 2027, will integrate Personalis' molecular residual disease (MRD) technology into Tempus' precision oncology platform. Personalis also reported preliminary Q2 2026 revenue of $22.4 million, with clinical test volumes increasing 33% to 10,384.
Key Highlights
- Personalis to be acquired by Tempus AI for $16.25 per share.
- Total enterprise value of the acquisition is $1.5 billion.
- Offer represents a 6% premium to Friday's closing price.
- Offer represents a 28% premium to unaffected 30-day VWAP.
- Consideration is primarily stock, with Tempus having a cash option up to 50%.
- Acquisition expected to close in late 2026 or early 2027.
- Personalis reported preliminary Q2 revenue of $22.4 million.
- Q2 clinical test volumes increased 33% quarter-over-quarter to 10,384.
Price Impact
More from PSNL